COMMUNIQUÉS West-GlobeNewswire

Adagene to Participate in Two Upcoming Investor Conferences
12/05/2026
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today [...]
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
12/05/2026
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Orchestra BioMed and Medtronic plc. (NYSE: MDT, “Medtronic”), the Company’s strategic [...]
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
12/05/2026
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
12/05/2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection
12/05/2026
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) ( [...]
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
12/05/2026
The first‑in‑class antibody program is designed to selectively target pathogenic cells, with the potential to deliver deeper and more durable disease control than current therapies. The agreement strengthens Boehringer [...]
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
12/05/2026
Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab Additional Phase 1b [...]
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
12/05/2026
Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients First clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the first quarter [...]
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
12/05/2026
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annual [...]
American Shared Hospital Services Announces First Quarter 2026 Financial Results Conference Call
12/05/2026
Call Scheduled for May 14th at 12:00 PM ET SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery [...]
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
12/05/2026
Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepted to FDA’s Rare [...]
Blue Point Brewing Launches Magic Hour IPA—A Bright, Tropical 6% ABV Sipper for Golden Hour
12/05/2026
New year-round American IPA balances hop-forward flavor with easy drinkability—available on draft and in 6-pack 12oz cans across NY, CT, PA & NJ PATCHOGUE, N.Y., May 12, 2026 (GLOBE NEWSWIRE) -- Blue Point Brewing [...]
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
12/05/2026
ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines that [...]
Sionna Therapeutics Reports First Quarter 2026 Financial Results
12/05/2026
Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of [...]
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
12/05/2026
Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U . S . -based Manufacturing [...]
ProQR Announces First Quarter 2026 Operating and Financial Results
12/05/2026
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the [...]
Felix Health to Lower Semaglutide Pricing by Up to 65% as Lower-Cost Options Enter Canada
12/05/2026
Canada’s largest virtual weight loss clinic says cost is causing patients to discontinue treatment: Nearly 1 in 4 Felix weight management patients who discontinued their program in the past year cited cost as the #1 [...]
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
12/05/2026
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogens Infex to present results from Phase IIa trial for first-in-class anti-virulence therapy [...]
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
12/05/2026
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appointed interim CEO Dr [...]

Pages